Detecting vulnerable plaque using peripheral blood: Inflammatory and cellular markers

Journal of Interventional Cardiology

Volumn 16, Issue 3, 2003, Pages 231-242

  Schwartz, Robert S ^a   Bayes Genis, Antonio ^a   Lesser, John R ^a   Sangiorgi, Massimo ^a   Henry, Timothy D ^a   Conover, Cheryl A ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE;

ATHEROSCLEROTIC PLAQUE; BLOOD; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; DISEASE MARKER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; UNSTABLE ANGINA PECTORIS; WOUND HEALING;

ARTERIES; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; CORONARY VESSELS; HUMANS; INFLAMMATION MEDIATORS; RISK FACTORS; RUPTURE, SPONTANEOUS;

EID: 0037864095     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0854.2003.8025.x     Document Type: Review

References (110)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104(23):2855-2864.
2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part 1: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104(22):2746-2753.
3. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20(5):1262-1275.
4. Virmani R, Burke AP, Farb A, et al. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002;44(5):349-356.
5. Diamond GA. Reverend Bayes' silent majority. An alternative factor affecting sensitivity and specificity of exercise electrocardiography. Am J Cardiol 1986;57(13):1175-1180.
6. Morise AP, Diamond GA. Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women. Am Heart J 1995;130(4):741-747.
7. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97(6):535-543.
8. Schwartz RS, Jackson WG, Celio PV, et al. Accuracy of exercise 201T1 myocardial scintigraphy in asymptomatic young men. Circulation 1993;87(1):165-172.
9. Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis: From laboratory evidence to clinical application. Ital Heart J 2001;2(11):796-800.
10. Muller JE, Abela GS, Nesto RW, et al. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23(3):809-813.
11. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336(18):1276-1282.
12. Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: A type of vulnerable plaque: The major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001;16(5):285-292.
13. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93(7):1354-1363.
14. Burke AP, Kolodgie FD, Farb A, et al. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002;105(3):297-303.
15. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89(9):763-771.
16. Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38(3):399-403.
17. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: An epidemiologic view. Blood Coagul Fibrinolysis 1999;10(Suppl 1):S9-S12.
18. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002;87(3):201-204.
19. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-1143.
20. Glurich I, Grossi S, Albini B, et al. Systemic inflammation in cardiovascular and periodontal disease: Comparative study. Clin Diagn Lab Immunol 2002;9(2):425-432.
21. Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: A novel therapeutic target. J Clin Pharmacol 1997;37(11):991-1000.
22. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92(6):1565-1569.
23. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94(6):2493-2503.
24. Engstrom G, Lind P, Hedblad B, et al. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002;105(22):2632-2637.
25. Westhuyzen J, Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000;30(2):133-143.
26. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation 2002;105(17):2019-2023.
27. Stenvinkel P, Barany P, Heimburger O, et al. Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 2002:80(Suppl):103-108.
28. Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women?. Ann Intern Med 2002;136(7):529-533.
29. Reuben DB, Ferrucci L, Wallace R, et al. The prognostic value of serum albumin in healthy older persons with low and high serum interleukin-6 (IL-6) levels. J Am Geriatr Soc 2000;48(11):1404-1407.
30. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19(10):2355-2363.
31. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99(7):855-860.
32. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101(3):252-257.
33. Dong Q, Wright J. Expression of C-reactive protein by alveolar macrophages. I Immunol 1996;156(12):4815-4820.
34. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001;69(3):1747-1754.
35. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158(3):1039-1051.
36. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. 2000;20(9):2094-2099.
37. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103(13):1813-1818.
38. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. 1998;18(9):1386-1392.
39. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102(18):2165-2168.
40. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001;103(9):1194-1197.
41. Zebrack JS, Muhlestein JB, Horne BD, et al. C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39(4):632-637.
42. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84(1):149-161, ix.
43. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 1997;349(9050):462-466.
44. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99(2):237-242.
45. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project. 1997;17(6):1121-1127.
46. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336(14):973-979.
47. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000;140(2):324-328.
48. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol, 2000;35(6):1535-1542.
49. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331(7):417-424.
50. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97(5):425-428.
51. Koh KK, Schenke WH, Waclawiw MA, et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002;105(13):1531-1533.
52. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103(4):491-495.
53. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17(10):2167-2176.
54. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327-334.
55. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282(22):2131-2135.
56. Ford E. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22(12):1971-1977.
57. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19(4):972-978.
58. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001;88(2):112-117.
59. Jialal I, Devaraj S. Inflammation and atherosclerosis: The value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001;116 (Suppl):S108-S115.
60. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37(5):1266-1270.
61. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100(8):793-798.
62. Bermudez EA, Ridker PM. C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 2002;5(1):42-46.
63. Bickel C, Rupprecht HJ, Blankenberg S, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89(8):901-908.
64. Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002;48(6):877-883.
65. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103(7):926-933.
66. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98(9):839-844.
67. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001;52(2):290-298.
68. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103(21):2531-2534.
69. Ikeda U, Ito T, Shimada K. Statins and C-reactive protein. Lancet 1999;353(9160):1274-1275.
70. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378(3/4):151-160.
71. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98(11):2572-2579.
72. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001;103(7):993-999.
73. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000;36(3):325-329.
74. Laursen LS, Overgaard MT, Soe R, et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: Implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 2001;504(1/2):36-40.
75. Chen BK, Overgaard MT, Bale LK, et al. Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: Identification of a novel inducible inhibitor. Endocrinology 2002;143(4):1199-1205.
76. Soe R, Overgaard MT, Thomsen AR, et al. Expression of recombinant murine pregnancy-associated plasma protein-A (PAPP-A) and a novel variant (PAPP-Ai) with differential proteolytic activity. Eur J Biochem 2002;269(8):2247-2256.
77. Giudice LC, Conover CA, Bale L, et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: Evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab 2002;87(5):2359-2366.
78. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregancy-associated plasma protein-A as a marker of acute coronary syndromes. N Engl J Med 2001;345(14):1022-1029.
79. Bayes-Genis A, Schwartz RS, Lewis DA, et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001;21(3):335-341.
80. Schonbeck U, Varo N, Libby P, et al. Soluble CD-40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
81. Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998;56(Suppl 1):9-13; discussion 33.
82. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171(3):223-229.
83. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351(9096):88-92.
84. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101(15):1767-1772.
85. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) Study. Circulation 1997;96(12):4219-4225.
86. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000;36(2):423-426.
87. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997;17(3):505-512.
88. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285(19):2481-2485.
89. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265(3):621-636.
90. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99(16):2079-2084.
91. Haverkate F. C-reactive protein as cardiovascular risk factor. A discovery by ECAT. Clin Chem Lab Med 2000;38(10):1055.
92. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991;89(2/3):247-254.
93. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101(18):2149-2153.
94. van der Meer IM, de Maat MP, Bots ML, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: The Rotterdam Study. Arterioscler Thromb Vasc Biol 2002;22(5):838-842.
95. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101(25):2883-2888.
96. Liuzzo G, Vallejo AN, Kopecky SL, et al. Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 2001;103(11):1509-1514.
97. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100(21):2135-2139.
98. Bobryshev YV, Lord RS. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J Vasc Surg 2002;35(2):368-375.
99. Ciervo A, Visca P, Petrucca A, et al. Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease. Clin Diagn Lab Immunol 2002;9(1):66-74.
100. Kanwar RK, Kanwar JR, Wang D, et al. Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001;21(12):1991-1997.
101. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: An update. Trends Immunol 2001;22(12):665-669.
102. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144(6):537-547.
103. Taaffe DR, Harris TB, Ferrucci L, et al. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000;55(12):M709-M715.
104. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000;321(7255):199-204.
105. Lowe GD, Yarnell JW, Rumley A, et al. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21(4):603-610.
106. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105(15):1760-1763.
107. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31(7):1460-1465.
108. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96(12):4204-4210.
109. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104(9):992-997.
110. Mendall MA, Patel P, Ballam L, et al. C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ 1996;312(7038):1061-1065.